Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on March 22, 2024. The filing serves to announce the company's financial results for the fourth quarter and the full fiscal year ended December 31, 2023. The company is an emerging growth company incorporated in Delaware and trades on the NYSE American under the symbol AGE.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text. Consequently, no specific financial figures can be extracted from this document alone.
Material Changes
The filing does not detail specific material changes versus prior periods within the body text. It solely directs investors to the press release (Exhibit 99.1) for the announcement of results for the fourth quarter and fiscal year 2023.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes a standard disclaimer that statements containing words such as "may," "will," "believes," or "expects" are forward-looking and subject to risks and uncertainties.
- Risk Factors: The company directs readers to its periodic reports filed with the SEC under the heading "Risk Factors" for additional details on factors that could cause actual results to differ materially from anticipated results.
- Outlook: No specific guidance or management commentary regarding future performance is provided in the text of this 8-K.
Investor Verification Checklist
- Verify the correct company name is AgeX Therapeutics, Inc. (Ticker: AGE), as the input metadata incorrectly listed "Serina Therapeutics, Inc."
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for Q4 and FY 2023, as they are absent from the 8-K text.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check the company's most recent periodic reports (10-K or 10-Q) for detailed "Risk Factors" referenced in the disclaimer.